| Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 274.32 mm | 274.32 mm | 274.32 mm | 274.32 mm | 274.32 mm | 274.32 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 9.31 mm | 8.56 mm | 8.58 mm | 7.31 mm |
| Cash used (since last report) | n/a | n/a | 326.57 mm | 300.25 mm | 300.80 mm | 256.37 mm |
| Cash remaining | n/a | n/a | -52.26 mm | -25.94 mm | -26.49 mm | 17.95 mm |
| Runway (months of cash) | n/a | n/a | -5.6 | -3.0 | -3.1 | 2.5 |
| 13F holders | Current |
|---|---|
| Total holders | 7 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 501.99 mm |
| Total shares | 21.03 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| GILD Gilead Sciences | 14.51 mm | $315.35 mm |
| Frazier Life Sciences Public Fund | 1.79 mm | $60.06 mm |
| Longitude Capital Partners III | 1.48 mm | $80.50 mm |
| Frazier Life Sciences VIII | 1.06 mm | $23.09 mm |
| Venrock Healthcare Capital Partners II | 984.75 k | $0.00 |
| New Leaf Biopharma Opportunities I | 661.90 k | $14.39 mm |
| Mangrove Partners Master Fund | 548.87 k | $8.60 mm |
